Propel Bio Management LLC Sells 168,191 Shares of Zevra Therapeutics, Inc. $ZVRA

Propel Bio Management LLC reduced its stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 72.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 63,683 shares of the company’s stock after selling 168,191 shares during the period. Zevra Therapeutics makes up approximately 0.5% of Propel Bio Management LLC’s investment portfolio, making the stock its 19th biggest position. Propel Bio Management LLC owned about 0.11% of Zevra Therapeutics worth $571,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Adage Capital Partners GP L.L.C. raised its position in Zevra Therapeutics by 15.2% during the second quarter. Adage Capital Partners GP L.L.C. now owns 4,168,000 shares of the company’s stock valued at $36,720,000 after purchasing an additional 550,000 shares in the last quarter. Vanguard Group Inc. raised its position in Zevra Therapeutics by 4.4% during the third quarter. Vanguard Group Inc. now owns 3,083,362 shares of the company’s stock valued at $29,323,000 after purchasing an additional 130,676 shares in the last quarter. Nantahala Capital Management LLC raised its position in Zevra Therapeutics by 34.0% during the third quarter. Nantahala Capital Management LLC now owns 1,971,936 shares of the company’s stock valued at $18,753,000 after purchasing an additional 500,000 shares in the last quarter. Rubric Capital Management LP raised its position in Zevra Therapeutics by 60.8% during the second quarter. Rubric Capital Management LP now owns 1,958,318 shares of the company’s stock valued at $17,253,000 after purchasing an additional 740,584 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in Zevra Therapeutics by 3.2% during the fourth quarter. Geode Capital Management LLC now owns 1,341,681 shares of the company’s stock valued at $12,025,000 after purchasing an additional 41,341 shares in the last quarter. 35.03% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

ZVRA has been the topic of a number of research reports. Wall Street Zen cut shares of Zevra Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday. Weiss Ratings cut shares of Zevra Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a research note on Friday, May 22nd. Guggenheim boosted their target price on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Finally, BTIG Research initiated coverage on shares of Zevra Therapeutics in a research note on Monday, March 16th. They set a “buy” rating and a $23.00 target price on the stock. Seven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, Zevra Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $23.33.

Zevra Therapeutics Stock Down 5.0%

Shares of NASDAQ ZVRA opened at $10.61 on Friday. Zevra Therapeutics, Inc. has a twelve month low of $7.16 and a twelve month high of $13.16. The firm has a fifty day simple moving average of $10.32 and a 200 day simple moving average of $9.37. The company has a market capitalization of $627.26 million, a PE ratio of 5.33 and a beta of 0.91.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.18 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.12. Zevra Therapeutics had a net margin of 101.58% and a return on equity of 51.49%. The business had revenue of $36.22 million during the quarter, compared to analysts’ expectations of $31.96 million. As a group, equities analysts expect that Zevra Therapeutics, Inc. will post 0.56 earnings per share for the current fiscal year.

Zevra Therapeutics Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.